Literature DB >> 35460416

Clinical Pathways When Considering Antimicrobials for the Treatment of Mild-to-Moderate COVID-19.

Daniel S Krauth1,2.   

Abstract

Amidst a constrained supply of novel therapeutics for the outpatient treatment of mild-to-moderate COVID-19, clinicians face new challenges, especially among those practicing at overseas military treatment facilities. Although prescribers may be unfamiliar with these medications, appropriate use necessitates detailed query of patient symptomatology and familiarization with each drug's side effect profile. Risk stratification also requires careful consideration to patient-specific comorbidities and immunization status for determining whom to treat and how. In recognition of these complexities, a stepwise guide is provided here to aid clinicians in their management of outpatients with mild-to-moderate COVID-19. © The Association of Military Surgeons of the United States 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35460416     DOI: 10.1093/milmed/usac109

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.563


  1 in total

Review 1.  Paxlovid: Mechanism of Action, Synthesis, and In Silico Study.

Authors:  Mahrokh Marzi; Mohammad Kazem Vakil; Maryam Bahmanyar; Elham Zarenezhad
Journal:  Biomed Res Int       Date:  2022-07-07       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.